Postprandial GlucoseNCT07100977
A Clinical Trial to Investigate the Acute Effect of Bragg Apple Cider Vinegar Supplement on Blood Glucose Control in a Healthy Adult Population
A study testing Bragg ACV Supplement in people with Postprandial Glucose and Blood Glucose Concentration, run by Bragg Live Food Products at 1 site in Canada.
Trial summary
The goal of this clinical trial is to evaluate the efficacy of a Bragg ACV supplement on postprandial glucose excursion compared to a placebo following a standardized acute carbohydrate load. Participants will be asked to consume an apple cider vinegar supplement 10 minutes prior to a standardized meal. Read more about this study
- Who is it for?
- Ages 20 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Postprandial Glucose, Blood Glucose Concentration
- What is being tested?
- Bragg ACV Supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteCanada
- Study dates
- Jan 2026to Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males and females 20 - 65 years of age, inclusive
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
- Or,
- Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
Show all 20Show fewer
- Intrauterine devices
- Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Abstinence and agrees to use contraception if planning on becoming sexually active during the study
- Subjects with elevated fasting glucose > 5.6 mmol/L (> 100 mg/dL) and < 7.0 mmol/L (< 126 mg/dL) and/or elevated HbA1c (6.0-6.4%) and two or more of the other following markers associated with metabolic syndrome at screening:
- Abdominal obesity: waist circumference > 102 cm (40 inches) in men and > 88 cm (35 inches) in women
- Hypertension: systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg
- Elevated TG: > 150 mg/dL (1.7 mmol/L)
- Low HDL-C: < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/dL (1.29 mmol/L) in women
- Stable body weight defined as a <5% change in body weight in the three months prior to baseline, as assessed by the Qualified Investigator (QI)
- Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study
- Agrees to comply with dietary guidelines and study requirements prior to in-clinic visits
- Provided voluntary, written, informed consent to participate in the study
- Otherwise healthy as determined by medical history and laboratory results as assessed by the Qualified Investigator (QI).
Who cannot join
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal
- Poor venous access as assessed by the QI
- Current use of prescribed and/or OTC medications, supplements, and/or consumption of food/drinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
Show all 25Show fewer
- Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Type I or Type II diabetes
- Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
- History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
- Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
- Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
- Individuals with an autoimmune disease or are immune compromised as assessed by the QI
- Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
- Self-reported confirmation of blood/bleeding disorders as assessed by the QI
- Chronic inhalation or edible use of cannabinoid products (>1 time/month). Occasional users must agree to abstain from use while participating in the study
- Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
- Alcohol intake average of >2 standard drinks per day as assessed by the QI
- Alcohol or drug abuse within the last 12 months
- Clinically significant abnormal laboratory results at screening as assessed by the QI
- Blood donation or blood loss between 101 mL to 449 mL within 30 days prior to screening; blood donation of more than 450 mL within 90 days prior to screening; blood donation during the study or a planned donation within 3 months of the last study visit; or plasma donation (e.g., plasmapheresis) within 15 days prior to screening
- Participation in other clinical research studies 30 days prior to baseline as assessed by the QI
- Individuals who are unable to give informed consent
- Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
KGK Science Inc.
London, Ontario, N6B3L1
Marc Moulin, PhD, 2267819094, mmoulin@kgkscience.com
David Crowley, MD
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar Supplement on Blood Glucose Control in a Healthy Adult Population
The goal of this clinical trial is to evaluate the efficacy of a Bragg ACV supplement on postprandial glucose excursion compared to a placebo following a standardized acute carbohydrate load.
Participants will be asked to consume an apple cider vinegar supplement 10 minutes prior to a standardized meal.
- Conditions
- Postprandial Glucose, Blood Glucose Concentration
- Being tested
- Bragg ACV Supplement, Placebo
- Keywords
- Apple Cider Vinegar, Apple Cider Vinegar Supplement, Bragg Live Food Products
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bragg ACV SupplementDietary supplement
Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
PlaceboOther
Participants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal.
| Study group | Role | What they receive |
|---|---|---|
| Bragg ACV Supplement | Experimental | Bragg Apple Cider Vinegar (ACV) Supplement contains apple cider vinegar (standardized to 750 mg of acetic acid), zinc, and vitamin D. Receives: Dietary Supplement: Bragg ACV Supplement |
| Placebo | Placebo comparator | Placebo supplement contains microcrystalline cellulose. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in the incremental area under the curve (iAUC)(0 - 120 min) for venous blood glucose between Bragg ACV supplement and placebo following an acute carbohydrate load.
The difference in the incremental area under the curve (iAUC)(0 - 120 min) for venous blood glucose between Bragg ACV supplement and placebo following an acute carbohydrate load.
Measured: 0 and 120 minutes post dose
Secondary outcomes (3)
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in the maximum venous blood glucose concentration (Cmax)
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in the maximum venous blood glucose concentration (Cmax)
Measured: 0 and 120 minutes post dose
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in the AUC(0 - 120 min) for serum insulin
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in the AUC(0 - 120 min) for serum insulin
Measured: 0 and 120 minutes post dose
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in time to maximum concentration for serum insulin (Tmax)
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in time to maximum concentration for serum insulin (Tmax)
Measured: 0 and 120 minutes post dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2025
- Study startJan 2026 (estimated)
- Primary completionJan 2026 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postprandial GlucoseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bragg Live Food Products
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Responsible party
- Sponsor
- Investigators
- David Crowley, MD, Principal investigator, KGK Science Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07100977
- Sponsor's protocol ID
- 25BGCFA02
- Status last verified
- Jul 2025
- First submitted
- 28 Jul 2025
- Last updated
- 9 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar Supplement on Blood Glucose Control in a Healthy Adult Population
- ClinicalTrials.gov ID
- NCT07100977
- Acronym / sponsor ID
- 25BGCFA02
- Conditions
- Postprandial Glucose, Blood Glucose Concentration
- Keywords
- Apple Cider Vinegar, Apple Cider Vinegar Supplement, Bragg Live Food Products
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Bragg Live Food ProductsIndustry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Study start
- Jan 2026 (estimated)
- Primary completion
- Jan 2026 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 3 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the efficacy of a Bragg ACV supplement on postprandial glucose excursion compared to a placebo following a standardized acute carbohydrate load.
Participants will be asked to consume an apple cider vinegar supplement 10 minutes prior to a standardized meal.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bragg ACV Supplement | Experimental | Dietary Supplement: Bragg ACV SupplementBragg Apple Cider Vinegar (ACV) Supplement contains apple cider vinegar (standardized to 750 mg of acetic acid), zinc, and vitamin D. |
| Placebo | Placebo comparator | Other: PlaceboPlacebo supplement contains microcrystalline cellulose. |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Males and females 20 - 65 years of age, inclusive
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
- Or,
- Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Subjects with elevated fasting glucose > 5.6 mmol/L (> 100 mg/dL) and < 7.0 mmol/L (< 126 mg/dL) and/or elevated HbA1c (6.0-6.4%) and two or more of the other following markers associated with metabolic syndrome at screening:
Key exclusion criteria (25 listed)
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal
- Poor venous access as assessed by the QI
- Current use of prescribed and/or OTC medications, supplements, and/or consumption of food/drinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
- Unstable metabolic disease or chronic diseases as assessed by the QI
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bragg ACV SupplementParticipants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal. | Dietary supplement | Bragg ACV Supplement |
| PlaceboParticipants will be instructed to consume 1 capsule of either Bragg ACV Supplement or placebo 10 minutes prior to consumption of a standardized meal. | Other | Placebo |
Primary outcome
The difference in the incremental area under the curve (iAUC)(0 - 120 min) for venous blood glucose between Bragg ACV supplement and placebo following an acute carbohydrate load.
Time frame: 0 and 120 minutes post dose
The difference in the incremental area under the curve (iAUC)(0 - 120 min) for venous blood glucose between Bragg ACV supplement and placebo following an acute carbohydrate load.
3 secondary outcomes
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in the maximum venous blood glucose concentration (Cmax)
Time frame: 0 and 120 minutes post dose
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in the AUC(0 - 120 min) for serum insulin
Time frame: 0 and 120 minutes post dose
The difference between Bragg ACV supplement and placebo following an acute carbohydrate load in time to maximum concentration for serum insulin (Tmax)
Time frame: 0 and 120 minutes post dose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2026.
Related trials for Postprandial Glucose
Active, not recruiting
Postprandial Glycemic and GLP-1 Responses to Modified Full-sugar Drinks
Postprandial Glucose, GLP-1 Concentration
Not yet recruiting
A Crossover Study Evaluating the Postprandial Glycemic Response of Three Sweeteners in a Mixed Meal Setting
Postprandial Glucose, GI Tolerance
Recruiting
Effect of SugarLock® Peanut Skin Extract on Postprandial Blood Glucose Control
Blood Sugar (Glucose) Control, Postprandial Glucose
Not yet recruitingPhase 2
Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease
Postprandial Hypoglycemia, End-stage Renal Disease (ESRD)
Not yet recruiting
A1-Free vs. Conventional Milk Metabolic Response Study
Postprandial Glucose Response, Insulin Response
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Crowley, MD principal investigator
KGK Science Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bragg ACV Supplement in people with Postprandial Glucose and Blood Glucose Concentration, run by Bragg Live Food Products at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marc Moulin, PhD (2267819094, mmoulin@kgkscience.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in the incremental area under the curve (iAUC)(0 - 120 min) for venous blood glucose between Bragg ACV supplement and placebo following an acute carbohydrate load. (time frame: 0 and 120 minutes post dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026; AzTrials last refreshed its copy on 8 Nov 2026.